36
MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Embed Size (px)

Citation preview

Page 1: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

MAST

Safety (Domain 2)

Clinical Effectiveness (Domain 3)

Reinhard Prior, HIM, Berlin May 5, 2010

Page 2: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Basic principles of MAST

Strong consideration of the existing literature when implementing a new trial

Use of validated, and generally accepted outcomes

‘Holistic approach’ considering several domains (not only clinical effectiveness)

Page 3: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Effectiveness

”The ability to produce a desired result under real life

conditions”

“Pragmatic trial”

Page 4: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Efficacy

”The ability to produce a desired result under strictly

controlled conditions”

“Explanatory trial”

Page 5: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Which are the ‘desired results’ from a clinical point of view?

Page 6: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Generic outcomes

(Not disease-specific)

Page 7: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

All-cause mortality

All-cause morbidity

Generic Health related Qol instruments (SF-36/12, EQ-5D)

Health care service utilisation

Page 8: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

•Number of hospitalisations

•Number of hospital bed days

•Number of visits to emergency rooms

•Number of visits by specialists

•Number of visits by GPs

•Number of visits by nurses

Page 9: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Disease-specific outcomes

(not disease-specific)

Scores, Questionnaires,

HRQol-questionnaires

Depression scales

Objective measurements

Hb A1c, cholesterol

FEV1

NYHA-class, LVEF

Page 10: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Requirements for primary outcomes

• Must be suitable to statistical analysis

• Must be easy to collect

• When a score, must be available and validated in all local languages

Page 11: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

What has already been done?

Literature overview

Page 12: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 13: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 14: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

50% of studies: non randomization, no control group

8 % of studies: non randomized with control group

Paré et al.

Page 15: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Paré et al

Paré et al.

Page 16: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Paré et al

Paré et al.

Page 17: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Paré et al

Page 18: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Paré et al

Page 19: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Paré et al

Page 20: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 21: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 22: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 23: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 24: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 25: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 26: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

How can Renewing Health do it better?

Page 27: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Careful design considering the missing evidence and missing aspects (not just

replication of previous research)

Large scale

MAST

Page 28: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Patient / population ?

Intervention ?

Comparator ?

Outcomes ?

Page 29: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Levels of evidence:

RCT with large sample size RCT with small sample size

Prospective study with non randomized control groupRetrospective study with non randomized control group

Cohort studyCase control studyDescriptive studies

Case reports

Page 30: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Randomized controlled trial

Quasi experimental methods (‘matched comparison’)

Page 31: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 32: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 33: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 34: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010
Page 35: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

MAST

A basis to facilitate an integrated evaluation of those domains that have not been addressed or have been insufficiently adressed by previous

research.

Page 36: MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

Thank you!